Improving prediction of disease outcome for inflammatory bowel disease: progress through systems medicine

References

• Beattie RM, Croft NM, Fell JM, et al. Inflammatory bowel disease. Arch Dis Child. 2006 May;91(5):426–432.
   PubMed Web of Science ®Google Scholar
• Ashton JJ, Mossotto E, Ennis S, et al. Personalising medicine in inflammatory bowel disease-current and future perspectives. Transl Pediatr. 2019 Jan;8(1):56–69.
   PubMed Web of Science ®Google Scholar
• Burgess CJ, Henderson P, Jones GR, et al. Pediatric patients (less than age of 17 years) account for less than 1.5% of all prevalent inflammatory bowel disease cases. J Pediatr Gastroenterol Nutr. 2020 Oct;71(4):521–523.
   PubMed Web of Science ®Google Scholar
• Ghione S, Sarter H, Fumery M, et al. Dramatic increase in incidence of ulcerative colitis and Crohn’s disease (1988-2011): a population-Based study of french adolescents. Am J Gastroenterol. 2018 Feb;113(2):265–272.
   PubMed Web of Science ®Google Scholar
• Roberts SE, Thorne K, Thapar N, et al. A systematic review and meta-analysis of pediatric inflammatory bowel disease incidence and prevalence across Europe. J Crohns Colitis. 2020 Sep 7;14(8):1119–1148.
   PubMed Web of Science ®Google Scholar
• Ye Y, Manne S, Treem WR, et al. Prevalence of inflammatory bowel disease in pediatric and adult populations: recent estimates from large national databases in the United States, 2007-2016. Inflamm Bowel Dis. 2020 Mar 4;26(4):619–625.
   PubMed Web of Science ®Google Scholar
• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017 Apr 29;389(10080):1756–1770.
   PubMed Web of Science ®Google Scholar
• Panes J, Rimola J. Perianal fistulizing Crohn’s disease: pathogenesis, diagnosis and therapy. Nat Rev Gastroenterol Hepatol. 2017 Nov;14(11):652–664.
   PubMed Web of Science ®Google Scholar
• Yu YR, Rodriguez JR. Clinical presentation of Crohn’s, ulcerative colitis, and indeterminate colitis: symptoms, extraintestinal manifestations, and disease phenotypes. Semin Pediatr Surg. 2017 Dec;26(6):349–355.
   PubMed Web of Science ®Google Scholar
• Ma C, Sandborn WJ, D’Haens GR, et al. Discordance between patient-Reported outcomes and mucosal inflammation in patients with mild to moderate ulcerative colitis. Clin Gastroenterol Hepatol. 2020 Jul;18(8):1760–1768 e1.
   PubMed Web of Science ®Google Scholar
• Gatti S, Brennan M, Heuschkel R, et al. Assessing quality of care in pediatric inflammatory bowel disease: focusing on self-reported outcomes. Dig Liver Dis. 2015 Apr;47(4):347–348.
   PubMedGoogle Scholar
• Wiestler M, Kockelmann F, Kück M, et al. Quality of life is associated with wearable-Based Physical activity in patients with inflammatory bowel disease: a prospective, observational study. Clin Transl Gastroenterol. 2019 Nov;10(11):e00094.
   PubMedGoogle Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for Treat-to-Target. Am J Gastroenterol. 2015 Sep;110(9):1324–1338.
   PubMed Web of Science ®Google Scholar
• Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021 Feb 19;160(5):1570–1583.
   Web of Science ®Google Scholar
• Kirschner M. Systems medicine: sketching the landscape. Methods Mol Biol. 2016;1386:3–15.
   PubMedGoogle Scholar
• Aronson JK, Ferner RE. Biomarkers-A general review. Curr Protoc Pharmacol. 2017 Mar 17;76:9 23 1–9 23 17.
   Google Scholar
• Gupta V, Mohsen W, Chapman TP, et al. Predicting outcome in acute severe colitis - controversies in clinical practice in 2021. J Crohns Colitis. 2021 Jan 3. DOI:https://doi.org/10.1093/ecco-jcc/jjaa265.
   Google Scholar
• Jongsma MME, Aardoom MA, Cozijnsen MA, et al. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial. Gut. 2020 Dec 31. DOI:https://doi.org/10.1136/gutjnl-2020-322339.
   Google Scholar
• Hoekman DR, Stibbe JA, Baert FJ, et al. Long-term outcome of early combined immunosuppression versus conventional management in newly diagnosed Crohn’s disease. J Crohns Colitis. 2018 Apr 27;12(5):517–524.
   PubMed Web of Science ®Google Scholar
• Farmer RG, Whelan G, Fazio VW. Long-term follow-up of patients with Crohn’s disease. Relationship between the clinical pattern and prognosis. Gastroenterology. 1985 Jun;88(6):1818–1825.
   PubMed Web of Science ®Google Scholar
• Hyams JS, Grand RJ, Colodny AH, et al. Course and prognosis after colectomy and ileostomy for inflammatory bowel disease in childhood and adolescence. J Pediatr Surg. 1982 Aug;17(4):400–405.
   PubMed Web of Science ®Google Scholar
• Dulai PS, Peyrin-Biroulet L, Danese S, et al. Approaches to integrating biomarkers into clinical trials and care pathways as targets for the treatment of inflammatory bowel diseases. Gastroenterology. 2019 Oct;157(4):1032–1043 e1.
   PubMed Web of Science ®Google Scholar
• Kim B, Park SJ, Hong SP, et al. Proximal disease extension and related predicting factors in ulcerative proctitis. Scand J Gastroenterol. 2014 Feb;49(2):177–183.
   PubMed Web of Science ®Google Scholar
• Fumery M, Singh S, Dulai PS, et al. Natural history of adult ulcerative colitis in population-based Cohorts: a systematic review. Clin Gastroenterol Hepatol. 2018 Mar;16(3):343–356 e3.
   PubMed Web of Science ®Google Scholar
• Frolkis AD, Dykeman J, Negrón ME, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013 Nov;145(5):996–1006.
   PubMed Web of Science ®Google Scholar
• Meucci G, Vecchi M, Astegiano M, et al. The natural history of ulcerative proctitis: a multicenter, retrospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII). Am J Gastroenterol. 2000 Feb;95(2):469–473.
   PubMed Web of Science ®Google Scholar
• Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44(4):431–440.
   PubMed Web of Science ®Google Scholar
• Michener WM, Farmer RG, Mortimer EA. Long-term prognosis of ulcerative colitis with onset in childhood or adolescence. J Clin Gastroenterol. 1979 Dec;1(4):301–305.
   PubMed Web of Science ®Google Scholar
• Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. 2010 Jun;138(7):2282–2291.
   PubMed Web of Science ®Google Scholar
• Gasparetto M, Guariso G, Pozza LV, et al. Clinical course and outcomes of diagnosing inflammatory bowel disease in children 10 years and under: retrospective cohort study from two tertiary centres in the United Kingdom and in Italy. BMC Gastroenterol. 2016 Mar 15;16(1):35.
   PubMedGoogle Scholar
• Schechter A, Griffiths C, Gana JC, et al. Early endoscopic, laboratory and clinical predictors of poor disease course in Pediatric ulcerative colitis. Gut. 2015 Apr;64(4):580–588.
   PubMed Web of Science ®Google Scholar
• Orlanski-Meyer E, Aardoom M, Ricciuto A, et al. Predicting outcomes in pediatric ulcerative colitis for management optimization: systematic review and consensus statements from the pediatric inflammatory bowel disease-Ahead program. Gastroenterology. 2021 Jan;160(1):378–402 e22.
   PubMed Web of Science ®Google Scholar
• Gasparetto M, Wong-Spracklen V, Torrente F, et al. Early treatment response predicts outcome in pediatric ulcerative colitis: GASTROENTEROLOGY: INFLAMMATORY BOWEL DISEASE. J Pediatr Gastroenterol Nutr. 2018 Aug;67(2):217–220.
   PubMed Web of Science ®Google Scholar
• Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001 Jan;120(1):13–20.
   PubMed Web of Science ®Google Scholar
• Rieder F, Kugathasan S. Circulating antibodies against bacterial wall products: are there arguments for early immunosuppression? Dig Dis. 2012;30(Suppl 3):55–66.
   PubMedGoogle Scholar
• Fleshner PR, Vasiliauskas EA, Kam LY, et al. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut. 2001 Nov;49(5):671–677.
   PubMed Web of Science ®Google Scholar
• Fleshner P, Ippoliti A, Dubinsky M, et al. Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 2008 May;6(5):561–568.
   PubMed Web of Science ®Google Scholar
• Dabritz J, Bonkowski E, Chalk C, et al. Granulocyte macrophage colony-stimulating factor auto-antibodies and disease relapse in inflammatory bowel disease. Am J Gastroenterol. 2013 Dec;108(12):1901–1910.
   PubMed Web of Science ®Google Scholar
• Cesarini M, Collins GS, Rönnblom A, et al. Predicting the individual risk of acute severe colitis at diagnosis. J Crohns Colitis. 2017 Mar 1;11(3):335–341.
   PubMed Web of Science ®Google Scholar
• Florholmen JR, Johnsen K-M, Meyer R, et al. Discovery and validation of mucosal TNF expression combined with histological score - a biomarker for personalized treatment in ulcerative colitis. BMC Gastroenterol. 2020 Oct 2;20(1):321.
   PubMed Web of Science ®Google Scholar
• Thia KT, Sandborn WJ, Lewis JD, et al. Defining the optimal response criteria for the Crohn’s disease activity index for induction studies in patients with mildly to moderately active Crohn’s disease. Am J Gastroenterol. 2008 Dec;103(12):3123–3131.
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn’s disease. Gastroenterology. 2006 Mar;130(3):650–656.
   PubMed Web of Science ®Google Scholar
• Loly C, Belaiche J, Louis E. Predictors of severe Crohn’s disease. Scand J Gastroenterol. 2008 Aug;43(8):948–954.
   PubMed Web of Science ®Google Scholar
• Torres J, Caprioli F, Katsanos KH, et al. Predicting outcomes to optimize disease management in inflammatory bowel diseases. J Crohns Colitis. 2016 Dec;10(12):1385–1394.
   PubMed Web of Science ®Google Scholar
• Sands BE, Arsenault JE, Rosen MJ, et al. Risk of early surgery for Crohn’s disease: implications for early treatment strategies. Am J Gastroenterol. 2003 Dec;98(12):2712–2718.
   PubMed Web of Science ®Google Scholar
• Romberg-Camps MJ, Dagnelie PC, Kester ADM, et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol. 2009 Feb;104(2):371–383.
   PubMed Web of Science ®Google Scholar
• Allez M, Lemann M, Bonnet J, et al. Long term outcome of patients with active Crohn’s disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol. 2002 Apr;97(4):947–953.
   PubMed Web of Science ®Google Scholar
• Fiorino G, Morin M, Bonovas S, et al. Prevalence of bowel damage assessed by cross-Sectional imaging in early Crohn’s disease and its impact on disease outcome. J Crohns Colitis. 2017 Mar 1;11(3):274–280.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Loftus EV Jr., Colombel JF, et al. The natural history of adult Crohn’s disease in population-based cohorts. Am J Gastroenterol. 2010 Feb;105(2):289–297.
   PubMed Web of Science ®Google Scholar
• Van Rheenen PF, Aloi M, Assa A, Bronsky J, et al. The medical management of pediatric Crohn’s disease: an ECCO-ESPGHAN guideline update. J Crohns Colitis. 202115(2):171–194.
   Web of Science ®Google Scholar
• Main J, McKenzie H, Yeaman GR, et al. Antibody to Saccharomyces cerevisiae (bakers’ yeast) in Crohn’s disease. BMJ. 1988 Oct 29;297(6656):1105–1106.
   PubMedGoogle Scholar
• Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1998 Jun;42(6):788–791.
   PubMed Web of Science ®Google Scholar
• Sendid B, Quinton J-F, Charrier G, et al. Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn’s disease. Am J Gastroenterol. 1998 Aug;93(8):1306–1310.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Li C, Zhao X, et al. Anti-Saccharomyces cerevisiae antibodies associate with phenotypes and higher risk for surgery in Crohn’s disease: a meta-analysis. Dig Dis Sci. 2012 Nov;57(11):2944–2954.
   PubMed Web of Science ®Google Scholar
• Kansal S, Catto-Smith AG, Boniface K, et al. Variation of Gut Mucosal Microbiome with Anti-Saccharomyces cerevisiae antibody status in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2019 Dec;69(6):696–703.
   PubMed Web of Science ®Google Scholar
• Mow WS, Vasiliauskas EA, Lin Y-C, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn’s disease. Gastroenterology. 2004 Feb;126(2):414–424.
   PubMed Web of Science ®Google Scholar
• Hamilton AL, Kamm MA, De Cruz P, et al. Serologic antibodies in relation to outcome in postoperative Crohn’s disease. J Gastroenterol Hepatol. 2017 Jun;32(6):1195–1203.
   PubMed Web of Science ®Google Scholar
• Ricciuto A, Aardoom M, Orlanski-Meyer E, et al. Predicting outcomes in pediatric Crohn’s disease for management optimization: systematic review and consensus statements from the pediatric inflammatory bowel disease-Ahead program. Gastroenterology. 2021 Jan;160(1):403–436 e26.
   PubMed Web of Science ®Google Scholar
• Malham M, Lilje B, Houen G, et al. The microbiome reflects diagnosis and predicts disease severity in Pediatric onset inflammatory bowel disease. Scand J Gastroenterol. 2019 Aug;54(8):969–975.
   PubMed Web of Science ®Google Scholar
• Denson LA, Curran M, McGovern DPB, et al. Challenges in IBD research: precision medicine. Inflamm Bowel Dis. 2019 May 16;25(Suppl 2):S31–S39.
   PubMedGoogle Scholar
• Atreya R, Neurath MF, Siegmund B. Personalizing treatment in IBD: hype or reality in 2020? Can we predict response to anti-TNF? Front Med (Lausanne). 2020;7:517.
   PubMed Web of Science ®Google Scholar
• Aardoom MA, Veereman G, de Ridder L. A review on the use of Anti-TNF in children and adolescents with inflammatory bowel disease. Int J Mol Sci. 2019 May 23;20(10):2529.
   PubMed Web of Science ®Google Scholar
• Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014 May;14(5):329–342.
   PubMed Web of Science ®Google Scholar
• Friedrich M, Pohin M, Powrie F. Cytokine networks in the pathophysiology of inflammatory bowel disease. Immunity. 2019 Apr 16;50(4):992–1006.
   PubMed Web of Science ®Google Scholar
• Hyams JS, Davis Thomas S, Gotman N, et al. Clinical and biological predictors of response to standardized pediatric colitis therapy (PROTECT): a multicentre inception cohort study. Lancet. 2019 Apr 27;393(10182):1708–1720.
   PubMed Web of Science ®Google Scholar
• Arijs I, Li K, Toedter G, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut. 2009 Dec;58(12):1612–1619.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Colombel J-F, Bloomfield R, et al. Increased response and remission rates in short-duration Crohn’s disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010 Jul;105(7):1574–1582.
   PubMed Web of Science ®Google Scholar
• Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn’s disease. Aliment Pharmacol Ther. 2003 Jun 15;17(12):1451–1457.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Colombel J-F, D’Haens G, et al. Characterisation of Mucosal Healing with Adalimumab treatment in patients with moderately to severely active Crohn’s disease: results from the EXTEND Trial. J Crohns Colitis. 2017 Apr 1;11(4):425–434.
   PubMed Web of Science ®Google Scholar
• Singh N, Rosenthal CJ, Melmed GY, et al. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014 Oct;20(10):1708–1713.
   PubMed Web of Science ®Google Scholar
• Dupont-Lucas C, Sternszus R, Ezri J, et al. Identifying patients at high risk of loss of response to infliximab maintenance therapy in pediatric Crohn’s Disease. J Crohns Colitis. 2016 Jul;10(7):795–804.
   PubMed Web of Science ®Google Scholar
• Barre A, Colombel JF, Ungaro R. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. Aliment Pharmacol Ther. 2018 Apr;47(7):896–905.
   PubMed Web of Science ®Google Scholar
• Amini Kadijani A, Aghdaei HA, Sorrentino D, et al. Transmembrane TNF-alpha density, but not soluble TNF-alpha level, is associated with primary response to infliximab in inflammatory bowel disease. Clin Transl Gastroenterol. 2017 Sep 14;8(9):e117.
   PubMedGoogle Scholar
• Hlavaty T, PIERIK M, Henckaerts L, et al. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn’s disease. Aliment Pharmacol Ther. 2005 Oct 1;22(7):613–626.
   PubMed Web of Science ®Google Scholar
• Bank S, Andersen PS, Burisch J, et al. Genetically determined high activity of IL-12 and IL-18 in ulcerative colitis and TLR5 in Crohns disease were associated with non-response to anti-TNF therapy. Pharmacogenomics J. 2018 Jan;18(1):87–97.
   PubMed Web of Science ®Google Scholar
• Baird AC, Mallon D, Radford-Smith G, et al. Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy. World J Gastroenterol. 2016 Nov 7;22(41):9104–9116.
   PubMed Web of Science ®Google Scholar
• West NR, Hegazy AN, Owens BMJ, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017 May;23(5):579–589.
   PubMed Web of Science ®Google Scholar
• Verstockt **S, Verstockt B, Machiels K, et al. Oncostatin M is a biomarker of diagnosis, worse disease prognosis, and therapeutic nonresponse in inflammatory bowel disease. Inflamm Bowel Dis. 2021 Feb 24. DOI:https://doi.org/10.1093/ibd/izab032.
   Google Scholar
• Bertani L, Fornai M, Fornili M, et al. Serum oncostatin M at baseline predicts mucosal healing in Crohn’s disease patients treated with infliximab. Aliment Pharmacol Ther. 2020 Jul;52(2):284–291.
   PubMed Web of Science ®Google Scholar
• Vatn S, Carstens A, Kristoffersen AB, et al. fecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European multicentre study (IBD-Character). Scand J Gastroenterol. 2020 Oct;55(10):1146–1156.
   PubMed Web of Science ®Google Scholar
• Tavassoly I, Goldfarb J, Iyengar R. Systems biology primer: the basic methods and approaches. Essays Biochem. 2018 Oct 26;62(4):487–500.
   PubMed Web of Science ®Google Scholar
• Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996 Mar 15;271(5255):1582–1586.
   PubMed Web of Science ®Google Scholar
• Salvucci M, Würstle ML, Morgan C, et al. A stepwise integrated approach to personalized risk predictions in stage III colorectal cancer. Clin Cancer Res. 2017 Mar 1;23(5):1200–1212.
   PubMed Web of Science ®Google Scholar
• Khan N, Patel D, Shah Y, et al. A novel user-Friendly model to predict corticosteroid utilization in newly diagnosed patients with ulcerative colitis. Inflamm Bowel Dis. 2017 Jun;23(6):991–997.
   PubMed Web of Science ®Google Scholar
• Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003 Jan;114(1):39–43.
   PubMed Web of Science ®Google Scholar
• Morilla I, Uzzan M, Cazals-Hatem D, et al. Computational learning of microRNA-Based prediction of pouchitis outcome after restorative proctocolectomy in patients with ulcerative colitis. Inflamm Bowel Dis. 2021 Feb 20. DOI:https://doi.org/10.1093/ibd/izab030.
   Google Scholar
• Siegel CA, Horton H, Siegel LS, et al. A validated web-based tool to display individualised Crohn’s disease predicted outcomes based on clinical, serologic and genetic variables. Aliment Pharmacol Ther. 2016 Jan;43(2):262–271.
   PubMed Web of Science ®Google Scholar
• Siegel CA, Siegel LS, Hyams JS, et al. Real-time tool to display the predicted disease course and treatment response for children with Crohn’s disease. Inflamm Bowel Dis. 2011 Jan;17(1):30–38.
   PubMed Web of Science ®Google Scholar
• Kugathasan S, Denson LA, Walters TD, et al. Prediction of complicated disease course for children newly diagnosed with Crohn’s disease: a multicentre inception cohort study. Lancet. 2017 Apr 29;389(10080):1710–1718.
   PubMed Web of Science ®Google Scholar
• Park Y, Cheon JH, Park YL, et al. Development of a novel predictive model for the clinical course of Crohn’s disease: results from the CONNECT Study. Inflamm Bowel Dis. 2017 Jul;23(7):1071–1079.
   PubMed Web of Science ®Google Scholar
• Lee JC, Lyons PA, McKinney EF, et al. Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest. 2011 Oct;121(10):4170–4179.
   PubMed Web of Science ®Google Scholar
• Gasparetto M, Payne F, Nayak K, et al. Transcription and DNA Methylation patterns of blood-Derived CD8(+) T cells are associated with age and inflammatory bowel disease but do not predict prognosis. Gastroenterology. 2021 Jan;160(1):232–244 e7.
   PubMed Web of Science ®Google Scholar
• Kalla R, Adams AT, Bergemalm D, Vatn S, et al. Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease. J Crohns Colitis. 2021 15(5):699–708.
   PubMed Web of Science ®Google Scholar
• Salvador-Martin S, Kaczmarczyk B, Álvarez R, et al. whole transcription profile of responders to anti-TNF drugs in pediatric inflammatory bowel disease. Pharmaceutics. 2021 Jan 8;13(1):77.
   PubMed Web of Science ®Google Scholar
• Haberman Y, Tickle TL, Dexheimer PJ, et al. Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. J Clin Invest. 2014 Aug;124(8):3617–3633.
   PubMed Web of Science ®Google Scholar
• Ventin-Holmberg R, Eberl A, Saqib S, et al. Bacterial and fungal profiles as markers of infliximab drug response in inflammatory bowel disease. J Crohns Colitis. 2020 Dec 10. DOI:https://doi.org/10.1093/ecco-jcc/jjaa252.
   Google Scholar
• Borren NZ, Plichta D, Joshi AD, et al. Multi-”-Omics” profiling in patients with quiescent inflammatory bowel disease identifies biomarkers predicting relapse. Inflamm Bowel Dis. 2020 Sep 18;26(10):1524–1532.
   PubMed Web of Science ®Google Scholar
• Lloyd K, Papoutsopoulou S, Smith E, Stegmaier P, et al. Using systems medicine to identify a therapeutic agent with potential for repurposing in inflammatory bowel disease. Dis Model Mech. 2020 Nov 27;13(11). Available from: https://journals.biologists.com/dmm/article/13/11/dmm044040/225761/Using-systems-medicine-to-identify-a-therapeutic
   Web of Science ®Google Scholar